A study of the synergy effects of BRM-A, the principal component of EF2001 lactic acid bacterium, and Byakkokaninjinto, for atopic dermatitis.

A study of the synergy effects of BRM-A, the principal component of EF2001 lactic acid bacterium, and Byakkokaninjinto, for atopic dermatitis. - A study of the synergy effects of lactic acid bacterium dietary supplement with Byakkokaninjinto for atopic dermatitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028857

Enrollment

Registered

2017-08-31

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

BRM-A Dosage regimen: 2 times a day. Takes 1 pack(1000mg) per each dose. To be taken between meals. Administration period: 3 months Byakkokaninjinto extract fine granule Dosage regimen: 3 times a d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with atopic dermatitis 2.Patients who agree to participate in this study with a written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with serious underlying disease. 2.Patients currently taking lactic acid bacterium or any Kampo medicine. 3.Patients with adverse reactions to blood sampling. 4.Pregnant Patients. 5.Patients deemed inappropriate for the study by the blood-collecting Doctor.

Design outcomes

Primary

Measure	Time frame
Thymus and activationregulated chemokine (TARC)	—

Secondary

Measure	Time frame
Eosinophil count Immunoglobulin E (IgE) Lactate dehydrogenase (LDH) C-reactive protein (CRP) Leukocytes count Gamma-Glutamyl Transferase (Gamma-GT) Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT) Active-oxygen scavenging activity Visual Analog Scale (VAS) SCORing Atopic Dermatitis (SCORAD) Concomitant drug	—

Countries

Japan

Contacts

Public ContactHiroaki Nishijima

School of Pharmacy, Showa University Department of Healthcare and Regulatory Science

heiwado@nr.catv.ne.jp03-3784-8215

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026